PharmaCielo Ltd.
PCLO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.31% | -45.28% | -80.15% | -72.06% | -35.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.31% | -45.28% | -80.15% | -72.06% | -35.91% |
| Cost of Revenue | -31.06% | -39.30% | -41.23% | -34.21% | -10.98% |
| Gross Profit | 102.78% | 18.68% | -346.24% | -225.94% | -492.55% |
| SG&A Expenses | -40.38% | -40.75% | -41.79% | -31.31% | -25.24% |
| Depreciation & Amortization | 149.75% | 243.91% | -12.28% | -34.42% | -130.77% |
| Other Operating Expenses | 27.97% | -45.51% | -224.83% | -- | -- |
| Total Operating Expenses | -33.31% | -37.78% | -41.26% | -32.64% | -31.91% |
| Operating Income | 40.49% | 35.83% | 24.11% | 13.85% | 30.67% |
| Income Before Tax | -8.51% | 8.59% | 2.44% | -7.95% | 22.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.51% | 8.59% | 2.44% | -7.95% | 22.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.51% | 8.59% | 2.44% | -7.95% | 22.63% |
| EBIT | 40.49% | 35.83% | 24.11% | 13.85% | 30.67% |
| EBITDA | 35.56% | 34.77% | 21.52% | 13.17% | 31.94% |
| EPS Basic | -1.97% | 15.61% | 9.26% | -1.35% | 25.67% |
| Normalized Basic EPS | 24.85% | 33.41% | 25.53% | 15.40% | 33.60% |
| EPS Diluted | -1.97% | 15.61% | 9.26% | -1.35% | 25.67% |
| Normalized Diluted EPS | 24.85% | 33.41% | 25.53% | 15.40% | 33.60% |
| Average Basic Shares Outstanding | 6.51% | 8.39% | 7.37% | 6.02% | 4.38% |
| Average Diluted Shares Outstanding | 6.51% | 8.39% | 7.37% | 6.02% | 4.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
